Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 18/20 | 0.49 |
| ▸ | TACR3 | P29371 | 3/20 | 0.47 |
| ▸ | TACR2 | P21452 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372735 | 0.93 | TRPV4 (0.43) | TRPV4TACR3TACR2KCNH2CACNA1C | |
| SCHEMBL2372101 | 0.92 | TRPV4 (0.52) | TRPV4TACR3TACR2KCNH2CACNA1C | |
| SCHEMBL2373082 | 0.92 | TRPV4 (0.47) | TRPV4TACR3TACR2KCNH2CACNA1C | |
| SCHEMBL2372782 | 0.92 | TRPV4 (0.47) | TRPV4TACR3TACR2KCNH2CACNA1C | |
| SCHEMBL2373459 | 0.91 | TRPV4 (0.44) | TRPV4TACR3TACR2KCNH2CACNA1C | |
| SCHEMBL2372840 | 0.91 | TRPV4 (0.43) | TRPV4TACR3TACR2KCNH2CACNA1C | |
| SCHEMBL2372456 | 0.91 | TRPV4 (0.48) | TRPV4TACR3TACR2KCNH2CACNA1C | |
| SCHEMBL2372607 | 0.90 | TRPV4 (0.41) | TRPV4TACR3TACR2KCNH2CACNA1C | |
| SCHEMBL2373587 | 0.90 | TRPV4 (0.53) | TRPV4TACR3TACR2KCNH2CACNA1C | |
| SCHEMBL2372430 | 0.90 | TACR3 (0.50) | TRPV4TACR3TACR2KCNH2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011119704-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |